JP2023538402A - プロドラッグ特性を有する新規サイロシン誘導体 - Google Patents

プロドラッグ特性を有する新規サイロシン誘導体 Download PDF

Info

Publication number
JP2023538402A
JP2023538402A JP2023512327A JP2023512327A JP2023538402A JP 2023538402 A JP2023538402 A JP 2023538402A JP 2023512327 A JP2023512327 A JP 2023512327A JP 2023512327 A JP2023512327 A JP 2023512327A JP 2023538402 A JP2023538402 A JP 2023538402A
Authority
JP
Japan
Prior art keywords
psilocin
derivative
indol
derivative according
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538402A5 (https=
Inventor
マティアス グリユ，
Original Assignee
コンパス パスファインダー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102020121965.2A external-priority patent/DE102020121965A1/de
Application filed by コンパス パスファインダー リミテッド filed Critical コンパス パスファインダー リミテッド
Publication of JP2023538402A publication Critical patent/JP2023538402A/ja
Publication of JP2023538402A5 publication Critical patent/JP2023538402A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2023512327A 2020-08-21 2021-08-23 プロドラッグ特性を有する新規サイロシン誘導体 Pending JP2023538402A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102020121965.2A DE102020121965A1 (de) 2020-08-21 2020-08-21 Neuartige Derivate des Psilocins mit Prodrug-Eigenschaften
DE102020121965.2 2020-08-21
US202063118842P 2020-11-27 2020-11-27
US63/118,842 2020-11-27
PCT/EP2021/073303 WO2022038299A1 (en) 2020-08-21 2021-08-23 Novel psilocin derivatives having prodrug properties

Publications (2)

Publication Number Publication Date
JP2023538402A true JP2023538402A (ja) 2023-09-07
JP2023538402A5 JP2023538402A5 (https=) 2024-08-09

Family

ID=77739049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512327A Pending JP2023538402A (ja) 2020-08-21 2021-08-23 プロドラッグ特性を有する新規サイロシン誘導体

Country Status (14)

Country Link
US (1) US20230295086A1 (https=)
EP (1) EP4200279A1 (https=)
JP (1) JP2023538402A (https=)
KR (1) KR20230054397A (https=)
CN (2) CN116075499B (https=)
AU (1) AU2021328726A1 (https=)
BR (1) BR112023003153A2 (https=)
CA (1) CA3188636A1 (https=)
CO (1) CO2023003282A2 (https=)
GB (2) GB2613993B (https=)
IL (1) IL300455A (https=)
MX (1) MX2023002133A (https=)
WO (1) WO2022038299A1 (https=)
ZA (1) ZA202301693B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
US12414936B2 (en) 2017-02-09 2025-09-16 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound
CA3152752A1 (en) 2019-10-01 2021-04-08 Thomas Henley Genetic engineering of fungi to modulate tryptamine expression
KR20220137081A (ko) 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
EP4255422A4 (en) 2020-12-03 2024-12-18 Mydecine Innovations Group Inc. NEW PSILOCIN ANALOGUE COMPOSITIONS AND METHODS OF THEIR SYNTHESIS
KR20230109765A (ko) * 2020-12-09 2023-07-20 캄테크, 인크. 다이알킬 트립타민 및 이의 치료적 용도
EP4155306A1 (en) 2021-01-15 2023-03-29 Beckley Psytech Limited Neuroactive ergoline analogue
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
JP2024534801A (ja) * 2021-08-20 2024-09-26 テラン バイオサイエンシズ インコーポレイテッド サイロシンのプロドラッグ及び誘導体ならびにその使用
EP4452939A4 (en) * 2021-12-24 2025-12-10 Kuleon Llc SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS
CN118984868A (zh) 2021-12-31 2024-11-19 恩派瑞安神经科学公司 用于产生精神药物生物碱的遗传修饰的生物体
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
AU2023234202A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. Salts of c4-carboxylic acid- and c4-carbonothioate-substituted tryptamine derivatives and methods of using
US11707447B1 (en) 2022-03-18 2023-07-25 Enveric Biosciences Canada Inc. C4-carbonothioate-substituted tryptamine derivatives and methods of using
WO2023173196A1 (en) * 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
CA3248442A1 (en) * 2022-04-13 2023-10-19 Caamtech, Inc. TRYPTAMINE DERIVATIVES
WO2023219789A1 (en) * 2022-05-10 2023-11-16 Mydecine Innovations Group Inc. Novel psilocin prodrug compounds and methods of synthesizing the same
AU2023269880A1 (en) * 2022-05-10 2024-01-18 Mydecine Innovations Group Inc. Novel psilocin prodrug compounds and methods of synthesizing the same
US11981637B2 (en) * 2022-06-09 2024-05-14 Caamtech, Inc. 4-pivaloyloxy-n-methyltryptammonium chloride
AU2023319280A1 (en) * 2022-08-05 2025-03-20 Mindset Pharma Inc. 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto
CN120091999A (zh) * 2022-08-05 2025-06-03 思维模式制药公司 作为血清素能剂用于治疗相关病症的3-吡咯烷-吲哚二聚体
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
US20260085040A1 (en) * 2022-09-12 2026-03-26 Bionxt Solutions Inc. Amino acid and carbohydrate psilocin derivatives
US20240269113A1 (en) * 2023-01-24 2024-08-15 Compass Pathfinder Limited 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
EP4592276A1 (en) 2024-01-29 2025-07-30 Universität Heidelberg Novel acyloxymethyl prodrugs of psilocin and related 4-hydroxytryptamines obtained by an efficient synthetic approach

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506246A (ja) * 2017-02-09 2020-02-27 カームテック、エルエルシー シロシビン誘導体を含む組成物及び方法
WO2021155470A1 (en) * 2020-02-04 2021-08-12 Mindset Pharma Inc. Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075992A (en) * 1958-09-12 1963-01-29 Sandoz Ltd Esters of indoles
CH386442A (de) 1959-03-18 1965-01-15 Ciba Geigy Verfahren zur Herstellung neuer 7-Aza-benzimidazole
US7655691B2 (en) * 2004-09-27 2010-02-02 Sard Howard P Indole compounds useful as serotonin selective agents
CA2666149A1 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
JP2024534801A (ja) * 2021-08-20 2024-09-26 テラン バイオサイエンシズ インコーポレイテッド サイロシンのプロドラッグ及び誘導体ならびにその使用
US20240269113A1 (en) * 2023-01-24 2024-08-15 Compass Pathfinder Limited 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES
TW202525777A (zh) * 2023-08-25 2025-07-01 英商康派斯開拓者公司 ３－（２－（二甲基胺基）乙基）－１ｈ－吲哚－４－基衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506246A (ja) * 2017-02-09 2020-02-27 カームテック、エルエルシー シロシビン誘導体を含む組成物及び方法
WO2021155470A1 (en) * 2020-02-04 2021-08-12 Mindset Pharma Inc. Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
JP2023513680A (ja) * 2020-02-04 2023-04-03 マインドセット ファーマ インコーポレイテッド 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADVANCED DRUG DELIVERY REVIEWS, vol. 65, no. 10, JPN6025023631, 2013, pages 1370 - 1385, ISSN: 0005762867 *
CURRENT PHARMACEUTICAL DESIGN, vol. 16, no. 18, JPN6025023630, 2010, pages 2033 - 2052, ISSN: 0005762866 *
SYNTHESIS, vol. 1999, no. 06, JPN6025023629, 1999, pages 935 - 938, ISSN: 0005762865 *

Also Published As

Publication number Publication date
CO2023003282A2 (es) 2023-04-17
IL300455A (en) 2023-04-01
WO2022038299A1 (en) 2022-02-24
EP4200279A1 (en) 2023-06-28
CA3188636A1 (en) 2022-02-24
KR20230054397A (ko) 2023-04-24
MX2023002133A (es) 2023-05-12
CN120904096A (zh) 2025-11-07
BR112023003153A2 (pt) 2023-04-04
CN116075499B (zh) 2025-07-25
GB2613993B (en) 2024-10-09
GB2632056A (en) 2025-01-22
GB2613993A (en) 2023-06-21
GB202412449D0 (en) 2024-10-09
AU2021328726A1 (en) 2023-03-02
ZA202301693B (en) 2026-01-28
CN116075499A (zh) 2023-05-05
GB2632056B (en) 2025-04-16
US20230295086A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
JP2023538402A (ja) プロドラッグ特性を有する新規サイロシン誘導体
KR102522895B1 (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
CN114728899A (zh) 新型三苯基化合物盐
TWI899078B (zh) Btk抑制劑之結晶形狀
US20230286975A1 (en) Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof
TW201736343A (zh) １－（５－（２，４－二氟苯基）－１－（（３－氟苯基）磺醯基）－４－甲氧基－１ｈ－吡咯－３－基）－ｎ－甲基甲胺鹽之新穎晶形
CN108727347B (zh) 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
BR112013013179B1 (pt) Polimorfo quimicamente puro de nor-udca, seu uso e seu método de preparação, e composição farmacêutica
JP3231775B2 (ja) 心循環器系に作用する２−アミノ−１，２，３，４−テトラヒドロナフタレン誘導体、それらを製造する方法、及びそれらを含む医薬組成物
EP2751094B1 (en) Novel crystal form
US20110144154A1 (en) Salts of 2-Substituted Quinolines
BR122026001062A2 (pt) Derivados de psilocina que apresentam propriedades pró-fármaco, seu uso e seu método de produção
EA051598B1 (ru) Новые производные псилоцина, обладающие свойствами пролекарств
US8710078B2 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride
DE102020121965A1 (de) Neuartige Derivate des Psilocins mit Prodrug-Eigenschaften
RU2828460C2 (ru) Кристаллические формы ингибитора btk
HUE028550T2 (en) Polymorphs of 6- (Piperidin-4-yloxy) -2H-isoquinolin-1-one hydrochloride
WO2019099761A1 (en) Solid state forms of elafibranor
WO2022191092A1 (ja) キノリン化合物、ｈｎｍｔ阻害剤、及びａｄｈｄ、ナルコレプシー又はアルツハイマーの予防・治療剤
US20110313044A1 (en) Polymorphs of Suberoylanilide Hydroxamic Acid
JP2001515067A (ja) 結晶１０，１０−ビス（（２−フルオロ−４−ピリジニル）メチル）−９（１０ｈ）−アントラセノンおよびその改良製法
CN113906016A (zh) 选择性组胺h3拮抗剂酸加成盐及其制备方法
NZ620864B2 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
HK1192546B (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
HK1198534B (en) Novel crystal form

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250612

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260306